Enanta Pharmaceuticals, Inc. $ENTA Shares Purchased by Spruce Street Capital LP

Spruce Street Capital LP boosted its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 139.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 932,598 shares of the biotechnology company's stock after purchasing an additional 542,911 shares during the quarter. Enanta Pharmaceuticals makes up approximately 2.8% of Spruce Street Capital LP's holdings, making the stock its 13th largest holding. Spruce Street Capital LP owned about 3.21% of Enanta Pharmaceuticals worth $11,779,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Meeder Asset Management Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $32,000. Seven Fleet Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth $36,000. Strs Ohio acquired a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Enanta Pharmaceuticals by 333.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 2,758 shares in the last quarter. Finally, Quarry LP acquired a new position in Enanta Pharmaceuticals during the 3rd quarter worth $81,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $12.78 on Friday. Enanta Pharmaceuticals, Inc. has a 1 year low of $6.45 and a 1 year high of $17.15. The stock has a market cap of $371.64 million, a price-to-earnings ratio of -4.93 and a beta of 0.96. The business has a fifty day moving average of $13.20 and a 200-day moving average of $13.44.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. The business had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. On average, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -1.79 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, May 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $20.29.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.